InMed Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
InMed Pharmaceuticals's earnings have been declining at an average annual rate of -6.3%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 85.8% per year.
Key information
-6.3%
Earnings growth rate
29.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 85.8% |
| Return on equity | -49.7% |
| Net Margin | -115.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M
Sep 26InMed Pharma announces $6M private placement
Sep 09InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens
Jul 25InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement
Jul 13InMed To Acquire Rare Cannabinoid Manufacturer BayMedica
Jul 02InMed's INM-755 CBN cream did not introduce any delay in normal wound healing
Jan 08Revenue & Expenses BreakdownBeta
How InMed Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5 | -6 | 5 | 3 |
| 30 Sep 23 | 5 | -7 | 6 | 4 |
| 30 Jun 23 | 4 | -8 | 6 | 4 |
| 31 Mar 23 | 2 | -15 | 6 | 5 |
| 31 Dec 22 | 2 | -17 | 6 | 5 |
| 30 Sep 22 | 1 | -19 | 7 | 7 |
| 30 Jun 22 | 1 | -19 | 7 | 7 |
| 31 Mar 22 | 1 | -14 | 7 | 7 |
| 31 Dec 21 | 0 | -14 | 6 | 8 |
| 30 Sep 21 | 0 | -12 | 5 | 6 |
| 30 Jun 21 | 0 | -10 | 4 | 5 |
| 31 Mar 21 | 0 | -9 | 3 | 5 |
| 31 Dec 20 | 0 | -7 | 3 | 4 |
| 30 Sep 20 | 0 | -8 | 3 | 5 |
| 30 Jun 20 | 0 | -9 | 3 | 6 |
| 31 Mar 20 | 0 | -10 | 4 | 7 |
| 31 Dec 19 | 0 | -11 | 5 | 7 |
| 30 Sep 19 | 0 | -10 | 5 | 6 |
| 30 Jun 19 | 0 | -10 | 6 | 4 |
| 31 Mar 19 | 0 | -9 | 6 | 3 |
| 31 Dec 18 | 0 | -8 | 6 | 2 |
| 30 Sep 18 | 0 | -7 | 6 | 2 |
| 30 Jun 18 | 0 | -6 | 5 | 1 |
| 31 Mar 18 | 0 | -6 | 4 | 1 |
| 31 Dec 17 | 0 | -5 | 4 | 1 |
| 30 Sep 17 | 0 | -5 | 4 | 1 |
| 30 Jun 17 | 0 | -3 | 3 | 1 |
| 31 Mar 17 | 0 | -2 | 2 | 0 |
| 31 Dec 16 | 0 | -2 | 1 | 0 |
| 30 Sep 16 | 0 | -2 | 1 | 0 |
| 30 Jun 16 | 0 | -2 | 1 | 0 |
| 31 Mar 16 | 0 | -3 | 2 | 1 |
| 31 Dec 15 | 0 | -3 | 2 | 1 |
| 30 Sep 15 | 0 | -3 | 2 | 1 |
| 30 Jun 15 | 0 | -3 | 3 | 1 |
| 31 Mar 15 | 0 | -3 | 3 | 1 |
| 31 Dec 14 | 0 | -2 | 2 | 0 |
| 30 Sep 14 | 0 | -2 | 2 | 0 |
| 30 Jun 14 | 0 | -1 | 1 | 0 |
| 31 Mar 14 | 0 | 0 | 0 | 0 |
| 31 Dec 13 | 0 | 0 | 0 | 0 |
| 30 Sep 13 | 0 | 0 | 0 | 0 |
Quality Earnings: INM is currently unprofitable.
Growing Profit Margin: INM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INM is unprofitable, and losses have increased over the past 5 years at a rate of 6.3% per year.
Accelerating Growth: Unable to compare INM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: INM has a negative Return on Equity (-49.73%), as it is currently unprofitable.